ReleaseWire Connect

Celdara Medical, a clinical-stage biotechnology company focused on delivering products to patients, announced today that it has entered into a Cooperative Research and Development Agreement (CRADA) with the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) and The Geneva Foundation, 501(c)3 non-profit organization that advances military medical research. This collaboration is focused on the development of a therapeutic antibody cocktail candidate for the treatment of Sudan virus, using established animal models to test efficacy against viral infection. There are currently no available therapeutic countermeasures as a part of the U.S. Strategic National Stockpile for Sudan virus. "The advancement of this product will increase preparedness for an emerging infectious disease of global concern," said John M. Dye, Ph.D., Chief of Viral Immunology at USAMRIID, whose research is supported by The Geneva Foundation.

Celdara Medical announces the publication of new translational research in the American Journal of Transplantation indicating that a novel polymer therapeutic candidate, APP-103TM, is able to preserve kidney function in preclinical models of kidney ischemia reperfusion injury, including transplantation. The results of the study, led by experts at Brigham and Women's Hospital and Beth Israel Deaconess Medical Center, provides a potential opportunity for expanded criteria kidney donation and much-needed hope for the roughly 750,000 Americans suffering from End-Stage Renal Disease (ESRD) who are awaiting a life-saving transplant.

Celdara Medical, LLC today announced the launch of an online resource database for biomedical entrepreneurs: bioentrepreneurresources.com. This database was developed by the DRIVEN Accelerator Hub, an NIH-funded consortium led by Celdara Medical including 10 of the leading research institutions in the Northeast region (NH, VT, ME, DE, and RI). The database is open to biomedical entrepreneurs globally and contains resources from across the country. New resources are added by user submission and curated by DRIVEN.

Celdara Medical, LLC today announced that the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH) has awarded a three-year Small Business Innovation Research (SBIR) fast track award to fund the company's advancement of APP-103 for the treatment of acute kidney injury (AKI). This project builds on the inventions of co-collaborator Dr. Peter Kang at the Beth Israel Deaconess Medical Center in Boston.